References |
1. Osteoprotegerin: a novel secreted protein involved in
the regulation of bone density. Cell 1997; 89:309-19. |
2. A homologue of the TNF receptor and its ligand enhance T-cell
growth and dendritic-cell function. Nature 1997; 390:175-9. |
3. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory
factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;
95:3597-602. |
4. Osteoprotegerin inhibits osteolysis and
decreases skeletal tumor burden in syngeneic and nude mouse models of experimental
bone metastasis. Cancer Res 2001; 61:4432-6. |
5. Osteoprotegerin inhibits osteoclast formation and
bone resorbing activity in giant cell tumors of bone. Bone 2001; 28:370-7.
|
6.
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of
humoral hypercalcemia of malignancy. Cancer Res 2000; 60:783-7. |
7. Therapeutic efficacy
of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein
in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia
of malignancy. Cancer Res 2001; 61:2572-8. |
8. Osteoprotegerin
reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular
calcification by blocking a process resembling osteoclastogenesis. J Exp
Med 2000; 192:463-74. |
9. Osteoprotegerin and receptor activator
of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by
cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001;
40:623-30. |
10.
Studies of the mechanism by which the mechanical failure of polymethylmethacrylate
leads to bone resorption. J Bone Joint Surg Am 1993; 75:802-13. |
11.
Interleukin-1 production by activated macrophages surrounding loosened orthopaedic
implants: a potential role in osteolysis. Br J Rheumatol 1994; 33:309-16.
|
12. Bone formation and bone resorption in failed
total joint arthroplasties: histomorphometric analysis with histochemical
and immunohistochemical technique. J Orthop Res 1996; 14:473-82. |
13.
Response of three murine macrophage populations to particulate debris: bone
resorption in organ cultures. J Orthop Res 1994; 12:720-31. |
14. TRANCE
is a TNF family member that regulates dendritic cell and osteoclast function.
J Leukoc Biol 1999; 65:715-24. |
15. .
[Osteoclastogenesis inhibitory factor (OCIF)/OPG]. Nippon Rinsho 1998; 56:1435-9.
|
16.
Breast cancer cells interact with osteoblasts to support osteoclast formation.
Endocrinology 1999; 140:4451-8. |
17. Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell 1998; 93:165-76. |
18. Activated
T cells regulate bone loss and joint destruction in adjuvant arthritis through
osteoprotegerin ligand. Nature 1999; 402:304-9. |
19. Cancer cells responsible for humoral hypercalcemia express mRNA
encoding a secreted form of ODF/TRANCE that induces osteoclast formation.
Biochem Biophys Res Commun 2000; 269:532-6. |
20. Osteoprotegerin
inhibits prostate cancer-induced osteoclastogenesis and prevents prostate
tumor growth in the bone. J Clin Invest 2001; 107:1235-44. |
21. Human osteosarcoma-derived cell lines produce soluble
factor(s) that induces differentiation of blood monocytes to osteoclast-like
cells. Int Immunopharmacol 2002; 2:25-38. |
22.
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation
and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S
A 1999; 96:3540-5. |
23. RANK is the essential signaling receptor for
osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys
Res Commun 1998; 253:395-400. |
24.
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated
factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel
TRAF6 interaction motif. J Biol Chem 1999; 274:7724-31. |
25. The TRAF family of signal
transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol
Chem 1998; 273:28355-9. |
26. TRANCE,
a TNF family member, activates Akt/PKB through a signaling complex involving
TRAF6 and c-Src. Mol Cell 1999; 4:1041-9. |
27. RANKing
the importance of measles virus in Pagets disease. J Clin Invest 2000;
105:555-8. |
28.
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin
(OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Endocrinology 1998; 139:1329-37. |
29. osteoprotegerin-deficient mice develop early onset osteoporosis
and arterial calcification. Genes Dev 1998; 12:1260-8. |
30.
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Biochem Biophys Res Commun 1998; 247:610-5. |
31. Serum osteoprotegerin
levels are increased in patients with advanced prostate cancer. Clin Cancer
Res 2001; 7:2977-83. |
32.
Serum osteoprotegerin levels are reduced in patients with multiple myeloma
with lytic bone disease. Blood 2001; 98:2269-71. |
33. Myeloma cells induce imbalance
in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow
environment. Blood 2001; 98:3527-33. |
34.
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger
bone destruction and promote tumor progression. Proc Natl Acad Sci U S A
2001; 98:11581-6. |
35. Osteoprotegerin inhibits the development of osteolytic
bone disease in multiple myeloma. Blood 2001; 98:3534-40. |
36.
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal
pain and pain-related neurochemical reorganization of the spinal cord. Nat
Med 2000; 6:521-8. |
37. Osteoprotegerin diminishes advanced bone cancer pain.
Cancer Res 2001; 61:4038-47. |
38.
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic
osteolysis. J Bone Joint Surg Br 2001; 83:902-11. |
39. Osteoprotegerin inhibits in vitro mouse osteoclast formation
induced by joint fluid from failed total hip arthroplasty. J Biomed Mater
Res 2001; 58:393-400. |
40. Effect of anti-tumor necrosis factor-alpha gene therapy on wear
debris-induced osteolysis. J Bone Joint Surg Am 2001; 83-A:1789-97. |
41. The effect of a single
dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;
16:348-60. |
42.
Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum
Mol Genet 1994; 3:359-61. |
43. Mutations in TNFRSF11A, affecting the signal peptide
of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24:45-8. |